FY2025 Earnings Estimate for ARTL Issued By HC Wainwright

Artelo Biosciences, Inc. (NASDAQ:ARTL) – Stock analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of Artelo Biosciences in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($1.84) for the year, down from their prior forecast of ($1.61). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Artelo Biosciences’ current full-year earnings is ($2.62) per share.

A number of other brokerages also recently weighed in on ARTL. LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th. D. Boral Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Artelo Biosciences in a research note on Thursday, February 27th.

Artelo Biosciences Stock Down 1.4 %

NASDAQ ARTL opened at $1.02 on Thursday. The company has a market capitalization of $3.29 million, a price-to-earnings ratio of -0.36 and a beta of 1.06. The stock has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.15. Artelo Biosciences has a twelve month low of $0.91 and a twelve month high of $1.70.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43).

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.